Physician profile
Whitney Brown
NPI 1972681096
$1,654.95
in general payments reported to CMS, 2019-2025
30 companies · $593 in 2025
The $593 reported for 2025 was more than what a typical Pediatric Endocrinology provider received nationally (typical 2025 total: $294).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2020: $124 · 2021: $97.00 · 2022: $223 · 2023: $236 · 2024: $277 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,105.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,105.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $225.88 | 2021-2025 | Lupron Depot |
| Medtronic Minimed, INC. | $152.97 | 2019-2020 | |
| Kyowa Kirin, INC. | $138.80 | 2023-2024 | Crysvita |
| Sanofi-Aventis U.S. LLC | $100.21 | 2024-2025 | |
| Ascendis Pharma Endocrinology INC | $91.92 | 2023-2025 | Skytrofa |
| Pfizer INC. | $86.97 | 2023-2025 | |
| Dexcom, INC. | $83.96 | 2022-2025 | Dexcom G6 Transmitter |
| Beta Bionics, INC. | $76.46 | 2023-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Endo USA, INC. | $73.50 | 2024-2025 | Supprelin |
| Novo Nordisk INC | $65.95 | 2023-2025 | Sogroya, Wegovy |
| Tandem Diabetes Care, INC. | $64.49 | 2019-2025 | T:Slim X2 Insulin Pump With Control-Iq |
| Abbott Laboratories | $50.51 | 2021-2023 | Freestyle Libre 3 |
| Biomarin Pharmaceutical INC. | $48.63 | 2023-2025 | Voxzogo 1.2mg |
| Rhythm Pharmaceuticals, INC. | $46.51 | 2022-2023 | Imcivree |
| Insulet Corporation | $38.99 | 2022-2023 | Omnipod |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Soleno Therapeutics, INC. | $35.00 | 2025 | Vykat Xr |
| Lilly USA, LLC | $33.56 | 2019-2023 | Lyumjev, Baqsimi |
| Endo Pharmaceuticals INC. | $26.23 | 2019-2021 | |
| Tolmar, INC. | $23.92 | 2025 | Fensolvi |
| Sequel Med Tech, LLC | $23.60 | 2025 | Twiist |
| Neurocrine Biosciences, INC. | $23.49 | 2025 | |
| Amphastar Pharmaceuticals, INC. | $19.66 | 2025 | |
| Becton, Dickinson and Company | $19.38 | 2019 | |
| Eton Pharmaceuticals, INC. | $18.66 | 2025 | Alkindi, Increlex, Khindivi |
| Alexion Pharmaceuticals, INC. | $18.10 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.62 | 2022 | |
| Ferring Pharmaceuticals INC. | $14.04 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.46 | 2021 | |
| Medtronic, INC. | $12.28 | 2021 | |
| Amneal Pharmaceuticals LLC | $12.20 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Whitney Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.